HLA Summer School Oral Presentation Asia-Pacific Histocompatibility and Immunogenetics Association Meeting 2023

Serological evaluation of acid treated platelets for removal of HLA Class I antigens (95906)

Penny Hassell 1 , April Davis 2 , Renée Rawson 2 , Nilam Devikashri 1 , Mark Burton 1 , David Mahon 1 , Denese C Marks 2 , James Daly 3 , Gail Pahn 1
  1. Transplantation & Immunogenetics, Australian Red Cross Lifeblood, Kelvin Grove, QLD, Australia
  2. Research & Development, Australian Red Cross Lifeblood, Sydney, NSW, Australia
  3. Pathology & Clinical Governance, Australian Red Cross Lifeblood, Kelvin Grove, QLD, Australia

Background:

HLA Class I (HLA-CI) antigens are expressed on platelets. Immune factors are found in 10-25% of platelet refractoriness patients, with antibodies to HLA-CI the most common cause.

These patients can become highly immunised, making compatibility searches difficult because of limited number and availability of suitable donors.

HLA-CI antigen depletion from the surface of platelets using citric acid may provide an alternative product to support these highly immunised patients.

Aim:

To investigate the effect of HLA-CI antigen depletion in platelet components using flow cytometry (IFT) and ELISA assays.

Method:

One unit from a double apheresis platelet collection (n=8 pairs) was treated with citric acid solution (pH 3.0) and the other with saline (control). Components were sampled on day 5 post-collection and tested.

Platelet glycoprotein (GP) expression levels were assessed by flow cytometry. Sera containing strong and weak HLA-CI antibodies were tested by flow cytometry and ELISA. Sera containing antibodies to HPA-1a, HPA-5a and -5b was also tested.

Results:

A significant reduction in HLA-ABC was observed following citric acid treatment (Table 1). Significant reductions in GPIIb/IIIa (CD41) and GPIb/IX (CD42a) expression were also observed.

Weak and strong HLA-CI antisera reactivity showed significant reductions by IFT and ELISA. Significant ELISA reductions were not observed, nor expected, with HPA-1a, -5a and -5b antisera due to the ELISA assay ability to discriminate between HPA and HLA antibodies. IFT cannot discriminate between the two.

                                                IFT (average MFI)
Glycoprotein expression       Saline                 ACID           p-value
CD41 (GPIIb/IIIa)            4330 ± 1527       3647 ± 1521     0.004*
CD42a (GPIb/IX)              4469 ± 2692       4174 ± 2505     0.015*
HLA-ABC                            6162 ± 1259      1037 ± 447       <0.0001*


                                             IFT (average MFI)                                                ELISA (Ratio)
Antisera                             Saline                ACID                 p-value           Saline             ACID              p-value
HPA-1a                              12.0 ± 6.8         7.0 ± 2.3           0.025*            80.3 ± 31.3    58.3 ± 12.3    0.054348448
HPA-5a                              7.1± 4.3            4.8 ± 2.3           0.022*            17.9 ± 10.5    15.7 ± 9.7      0.326267511
HPA-5b                              3.9 ± 1.8           3.0 ± 1.2           0.043*            5.9 ± 11.3      4.2 ± 7.4       0.259711613
HLA class I (weak)           1.9 ± 0.9           0.9 ± 0.2            0.009*            7.61 ± 5.8      2.8 ± 2.8       0.011*
HLA class I (strong)          18.4 ± 7.5         5.6 ± 1.9           0.0004*          60.2 ± 15.1     17.9 ± 9.3     0.00015*

Table 1 Platelet glycoprotein expression and antisera reactivity changes after citric acid solution treatment. Data were analysed using paired t-tests, *indicates p<0.05 was considered significant. Data represent mean ± standard deviation (n=8).

Conclusion:

Significantly reduced HLA-CI antibody reactivity was seen in both IFT and ELISA assays following citric acid treatment. Further testing of acid treated platelets against a larger set of clinical platelet refractory samples is needed to progress development of this modified blood product.